Loading...
•
Mar 31, 2022
Jaguar Health Q1 2022 Earnings Report
Reported consolidated first quarter 2022 financial results and provided company updates.
Key Takeaways
Jaguar Health reported a 112% increase in Mytesi net revenue compared to Q1 2021, reaching $2.6 million, and Canalevia-CA1 is now commercially available.
Mytesi net revenue increased approximately 24% over the fourth quarter of 2021.
Mytesi net revenue was approximately $2.6 million in the first quarter of 2022.
Mytesi total prescription volume increased 14.6% in the first quarter of 2022 over the fourth quarter of 2021.
Canalevia-CA1, for chemotherapy-induced diarrhea in dogs, is now commercially available.
Jaguar Health
Jaguar Health
Forward Guidance
Jaguar Health anticipates continued development initiatives for crofelemer, efforts to forge license and business development relationships, the ongoing Canalevia-CA1 launch, potential expansion of Canalevia conditional approval to exercise-induced diarrhea (EID) in dogs; and continued growth in sales of Mytesi.
Positive Outlook
- Continued development initiatives for crofelemer
- Efforts to forge license and business development relationships
- Ongoing Canalevia-CA1 launch
- Potential expansion of Canalevia conditional approval to exercise-induced diarrhea (EID) in dogs
- Continued growth in sales of Mytesi